Table 1 Distribution of ATAD2 and Clinicopathological Characteristics in HCC patients
Characteristics | Number of patients | ATAD2 overexpression | Negative or weak expression | P |
|---|---|---|---|---|
Total cases | 129 | 83 | 46 | |
Age (years) | ||||
≥60 | 54 | 34(63.0%) | 20(37.0%) | 0.782 |
<60 | 75 | 49(65.3%) | 26(34.7%) | |
Gender | ||||
Male | 106 | 69(65.1%) | 37(34.9%) | 0.701 |
Female | 23 | 14(60.9%) | 9(39.1%) | |
Tumor size | ||||
≥ 5cm | 83 | 53(63.9%) | 30(36.1%) | 0.877 |
< 5cm | 46 | 30(65.2%) | 16(34.8%) | |
Metastasis | ||||
Yes | 72 | 54(75%) | 18(25%) | 0.005 |
No | 57 | 29(50.9%) | 28(49.1%) | |
HBsAg status | ||||
Positive | 73 | 43(58.9%) | 30(41.1%) | 0.141 |
Negative | 56 | 40(71.4%) | 16(28.6%) | |
Tumor differentiation | ||||
WD | 54 | 34(63.0%) | 20(37.0%) | 0.955 |
MD | 60 | 39(65.0%) | 21(35.0%) | |
PD | 15 | 10(66.7%) | 5(33.3%) | |
Cirrhosis | ||||
Yes | 86 | 58(67.4%) | 28(32.6%) | 0.298 |
No | 43 | 25(58.1%) | 18(41.9%) | |
Serum AFP | ||||
<200 ng/dl | 41 | 29(70.7%) | 12(29.3%) | 0.301 |
≥200 ng/dl | 88 | 54(61.4%) | 34(38.6%) | |
Tumor stage | ||||
TNM I+II | 42 | 25(59.5%) | 17(40.5%) | 0.427 |
TNM III+IV | 87 | 58(66.7%) | 29(33.3%) |